A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
about
Tissue Specific Promoters in Colorectal CancerThe proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxiaTargeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulationBikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatmentDe-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells.Antitumor effects of a dual cancer-specific oncolytic adenovirus on colorectal cancer in vitro and in vivoSequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice.Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasionOvarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplexCancer-specific binary expression system activated in mice by bacteriophage HK022 Integrase.Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth.Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy.Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy.nm23-H1 gene driven by hTERT promoter induces inhibition of invasive phenotype and metastasis of lung cancer xenograft in mice.Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly.Therapeutic effect of targeted Fas-expressing adenoviruses method combining γδ T cells in a mouse model of human ovarian carcinoma.Promoter-Operating Targeted Expression of Gene Therapy in Cancer: Current Stage and Prospect.
P2860
Q26773374-DD22CB62-3DF5-457C-9410-B543FF49606CQ33690020-C67EF383-0FE0-4219-B0DA-B2ED0B462E82Q33998169-608FC2BC-807D-4655-AD6A-C73F55E0A687Q34200411-A27BF2AF-C6FA-4BE5-B644-21DA888FAC0CQ34632169-B93061D4-59AE-4192-81D5-2375C3423957Q34786501-B757CE92-995B-4CE7-AEE8-A55EFEFF3D73Q34795642-6D037C5E-9EF2-4D50-8FCD-C2F8DD833C26Q34997857-C3B6F14D-6319-445F-B87A-59189306CA45Q36460483-BACAA1E8-7545-4558-B0B9-224A983C2304Q36776863-BE3077DF-D849-4B42-B66A-4D620F48DD83Q36841477-45F712C5-B4AA-4ADF-ABED-561EB1518DFCQ36934025-7F5C5250-80CC-444D-8FCE-3FDFDABFF16CQ39352993-F962AEBF-A218-4873-9E3D-F159D5448A3BQ39456135-57F59299-6AE3-4BD8-9F20-A847B0A6DF6AQ39806537-13BAEA4D-B681-43CE-A498-8663C85C9F1DQ45872057-5BADCB68-513B-4581-808C-89CBE78FF7E3Q47139128-AE72EA5C-0E7C-4D14-AA78-3103CA71F2C3Q49427808-68C2FB4B-2797-4510-A607-EC0FE1F13841Q55239952-BE270E02-3B2A-40DB-9D29-40A6BA14D6CF
P2860
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
@en
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
@nl
type
label
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
@en
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
@nl
prefLabel
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
@en
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
@nl
P2093
P2860
P1476
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer
@en
P2093
Bon Q Trinh
Chun-Te Chen
Hirohito Yamaguchi
Jennifer L Hsu
Judith K Wolf
Mien-Chie Hung
Min-Gew Choi
Naoto T Ueno
P2860
P304
P356
10.1158/1535-7163.MCT-09-0056
P577
2009-08-11T00:00:00Z